Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Fineline Cube Jul 6, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Simcere and Connect Biopharma’s Rademikibart NDA Accepted by China’s NMPA for Atopic Dermatitis

Fineline Cube Jul 10, 2025

The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s...

Company Deals

Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market

Fineline Cube Jul 10, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...

Company Deals Medical Device

ShuWen Biotech Completes RMB100 Million Series C1 Round to Advance Women’s Health Diagnostics

Fineline Cube Jul 10, 2025

Zhejiang-based ShuWen Biotech Co., Ltd announced the successful completion of an RMB100 million (USD 14...

Company Drug

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma

Fineline Cube Jul 10, 2025

China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...

Company Deals

MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio

Fineline Cube Jul 10, 2025

In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant...

Company Drug

Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA

Fineline Cube Jul 9, 2025

China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...

Company

Pascal Qian Appointed General Manager of BMS China Unit

Fineline Cube Jul 9, 2025

Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...

Company Deals

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates

Fineline Cube Jul 9, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to...

Company Deals

Zhaoke Ophthalmology Partners with Somerset Therapeutics to Accelerate US Expansion

Fineline Cube Jul 9, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced last month a strategic partnership with US generic...

Company Deals

LakeShore Biopharma Secures $15 Million in Private Placement to Fuel Growth

Fineline Cube Jul 9, 2025

China-based biopharmaceutical company LakeShore Biopharma Co., Ltd (NASDAQ: LSB) has announced the successful execution of...

Company Drug

Innovent’s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau

Fineline Cube Jul 9, 2025

China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with...

Company Deals

NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies

Fineline Cube Jul 9, 2025

China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for SHR-2173 in Primary Membranous Nephropathy

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Fineline Cube Jul 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...

Company Drug

Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants

Fineline Cube Jul 9, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic...

Company Drug

Jiangsu Hengrui Gains NMPA Clinical Clearance for HRS-9821 in COPD Treatment

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Policy / Regulatory

NMPA Updates Review Procedures for Conditional Drug Marketing Approval Applications

Fineline Cube Jul 9, 2025

The National Medical Products Administration (NMPA) this week released a revised draft proposal for the...

Company Medical Device

Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation

Fineline Cube Jul 9, 2025

US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for...

Company Drug

HutchMed Announces First Commercial Shipments of Tazverik Across China

Fineline Cube Jul 9, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...

Company Deals Medical Device

Shenzhen Concemed Medtech Secures Hundreds of Millions in Series A+ Funding for Endoscopy Expansion

Fineline Cube Jul 8, 2025

Shenzhen Concemed Medical Technology Co., Ltd., a China-based endoscope specialist, has reportedly secured “hundreds of...

Posts pagination

1 … 154 155 156 … 690

Recent updates

  • China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
  • Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment
  • Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.